Renal Cell Carcinoma and Targeted Therapy

Benjamin A. Gartrell, Alexander C. Small, William K. Oh, Matthew D. Galsky

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Renal cell carcinoma (RCC) is generally resistant to cytotoxic chemotherapy. Clear-cell RCC (ccRCC) is the most common histology accounting for 80-90% of tumors. This chapter explores the molecular pathogenesis of RCC, and the targeted therapies that have recently been developed. The genetics of VHL disease follow the "two hit" model of tumor suppressor gene function first proposed by Knudson. Next-generation sequencing has been used to evaluate tumor heterogeneity in RCC. The chapter talks about the important signaling pathways in RCC, including the mammalian target of the rapamycin (mTOR) pathway. Renal carcinoma is a vascular tumor and VEGF has been detected in high levels in the serum of patients with RCC. With elucidation of key molecular mechanisms of disease, vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptors (VEGFR) and target of the mTOR emerged as promising targets which have now been validated in large clinical trials.

Original languageEnglish
Title of host publicationTargeted Therapy in Translational Cancer Research
Number of pages9
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
StatePublished - 30 Oct 2015


  • Mammalian target
  • Rapamycin pathway
  • Renal cell carcinoma
  • Targeted therapy
  • Tumor suppressor gene function
  • Vascular endothelial growth factor


Dive into the research topics of 'Renal Cell Carcinoma and Targeted Therapy'. Together they form a unique fingerprint.

Cite this